An upper limit on the mass of the circumplanetary disk for DH Tau b

DH Tau is a young ($\sim$1 Myr) classical T Tauri star. It is one of the few young PMS stars known to be associated with a planetary mass companion, DH Tau b, orbiting at large separation and detected by direct imaging. DH Tau b is thought to be accreting based on copious H${\alpha}$ emission and exhibits variable Paschen Beta emission. NOEMA observations at 230 GHz allow us to place constraints on the disk dust mass for both DH Tau b and the primary in a regime where the disks will appear optically thin. We estimate a disk dust mass for the primary, DH Tau A of $17.2\pm1.7\,M_{\oplus}$, which gives a disk-to-star mass ratio of 0.014 (assuming the usual Gas-to-Dust mass ratio of 100 in the disk). We find a conservative disk dust mass upper limit of 0.42$M_{\oplus}$ for DH Tau b, assuming that the disk temperature is dominated by irradiation from DH Tau b itself. Given the environment of the circumplanetary disk, variable illumination from the primary or the equilibrium temperature of the surrounding cloud would lead to even lower disk mass estimates. A MCFOST radiative transfer model including heating of the circumplanetary disk by DH Tau b and DH Tau A suggests that a mass averaged disk temperature of 22 K is more realistic, resulting in a dust disk mass upper limit of 0.09$M_{\oplus}$ for DH Tau b. We place DH Tau b in context with similar objects and discuss the consequences for planet formation models.Comment: accepted for publication in A

Lambda = 3 mm line survey of nearby active galaxies

We used the IRAM 30m telescope to observe the frequency range [86-116]GHz towards the central regions of the starburst galaxies M83, M82, and NGC253, the AGNs M51, NGC1068, and NGC7469, and the ULIRGs Arp220 and Mrk231. Assuming LTE conditions, we calculated the column densities of 27 molecules and 10 isotopologues. Among others, we report the first tentative detections of CH3CHO, HNCO, and NS in M82 and, for the first time in the extragalactic medium, HC5N in NGC253. Halpha recombination lines were only found in M82 and NGC253. Vibrationally excited lines of HC3N were only detected in Arp220. CH3CCH emission is only seen in the starburst-dominated galaxies. By comparison of the fractional abundances among the galaxies, we looked for the molecules that are best suited to characterise the chemistry of starbursts, AGNs and ULIRGs, as well as the differences among galaxies within the same group.Comment: 24 pages, 6 figures, 12 tables. Accepted for publication in Astronomy and Astrophysic

COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study

Background: The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Methods: International, prospective observational study of 60 109 hospitalized symptomatic patients with laboratory-confirmed COVID-19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to evaluate relationships of age and sex to published COVID-19 case definitions and the most commonly reported symptoms. Results: ‘Typical’ symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most commonly reported. 92% of patients experienced at least one of these. Prevalence of typical symptoms was greatest in 30- to 60-year-olds (respectively 80, 79, 69%; at least one 95%). They were reported less frequently in children (≤ 18 years: 69, 48, 23; 85%), older adults (≥ 70 years: 61, 62, 65; 90%), and women (66, 66, 64; 90%; vs. men 71, 70, 67; 93%, each P < 0.001). The most common atypical presentations under 60 years of age were nausea and vomiting and abdominal pain, and over 60 years was confusion. Regression models showed significant differences in symptoms with sex, age and country. Interpretation: This international collaboration has allowed us to report reliable symptom data from the largest cohort of patients admitted to hospital with COVID-19. Adults over 60 and children admitted to hospital with COVID-19 are less likely to present with typical symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a frequent atypical presentation of COVID-19 in adults over 60 years. Women are less likely to experience typical symptoms than men

Multi-wavelength observations and modelling of a quiescent cloud LDN1512

Context. Light scattering at near-infrared (NIR) wavelengths has been used to study the optical properties of the interstellar dust grains, but these studies are limited by the assumptions on the strength of the radiation field. On the other hand, thermal dust emission can be used to constrain the properties of the radiation field, although this is hampered by uncertainty about the dust emissivity.Aims. Combining light scattering and emission studies allows us to probe the properties of the dust grains in detail. We wish to study if current dust models allow us to model a molecular cloud simultaneously in the NIR and far-infrared (FIR) wavelengths and compare the results with observations. Our aim is to place constraints on the properties of the dust grains and the strength of the radiation field.Methods. We present computations of dust emission and scattered light of a quiescent molecular cloud LDN1512. We use NIR observations covering the J, H, and K-S bands, and FIR observations between 250 and 500 mu m from the Herschel space telescope. We constructed radiative transfer models for LDN1512 that include an anisotropic radiation field and a three-dimensional cloud model.Results. We are able to reproduce the observed FIR observations, with a radiation field derived from the DIRBE observations, with all of the tested dust models. However, with the same density distribution and the assumed radiation field, the models fail to reproduce the observed NIR scattering in all cases except for models that take into account dust evolution via coagulation and mantle formation. The intensity from the diffuse interstellar medium like, dust models can be increased to match the observed one by reducing the derived density, increasing the intensity of the background sky and the strength of the radiation field between factors from two to three. We find that the column densities derived from our radiative transfer modelling can differ by a factor of up to two, compared to the column densities derived from the observations with modified blackbody fits. The discrepancy in the column densities is likely caused because of a temperature difference between a modified blackbody fit and the real spectra. The difference between the fitted temperature and the true temperature could be as high as Delta T = +1.5 K.Conclusions. We show that the observed dust emission can be reproduced with several different assumptions about the properties of the dust grains. However, in order to reproduce the observed scattered surface brightness, dust evolution must be taken into account.Peer reviewe

Longitudinal relations between young students’ feelings about mathematics and arithmetic performance

International audienc

Unveiling Grain Growth in Very Dense Galactic Cores

Interstellar dust provides the building blocks of planets and the initial grain size distribution in the parent molecular cloud is key to understanding how planets form. Under typical diffuse ISM conditions, dust grains do not grow beyond ~0.5 micron. However, within dense molecular clouds, when shielded from the harsh interstellar radiation field, ice mantles form, allowing grain growth through coagulation. Theoretical models predict that grain growth deforms the silicate band profiles at 9.7 and 18 micron and flattens the extinction curve between 5 and 26 micron. We propose to observe, with MIRI spectroscopy, 9 independent lines of sight through 3 very dense cores, from 5 to 40 mag of Av. Our proposed measurements, made possible by the exquisite JWST sensitivity, will be a paradigm shift in the field: the simultaneous observations of the 9.7 and 18 micron silicate absorption features at such high Av, of the 5-26 micron extinction curve, and of several ice features, coupled with state-of-the-art modelling, will allow us to resolve for the first time intrinsic degeneracies in grain size, shape and porosity. This will make it possible to set unprecedented constraints on astrochemical models with wide applications to planet and star formation. We will also deliver to the community a mini atlas of spectroscopic MIR extinction curves for the observed regions, which will be the very first publicly available for high Av sightlines. This program complements the current JWST ERS portfolio, by helping to bridge a critical gap between star and planet formation, making it an ideal addition to the Cycle 1 observations which promise to deliver revolutionary science

Collaborative study of a Supercritical Fluid Chromatography method for the determination of pharmaceutical impurities

Projet PHAR

Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial

International audienceBackground: Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP). In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non-CAP related septic shock.Methods: APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa (activated), or both on mortality in septic shock in a two-by-two factorial design; after drotrecogin-alfa was withdrawn on October 2011, from the market, the trial continued on two parallel groups. It was conducted in 34 centres in France. In this subgroup study, patients with CAP were a preselected subgroup for an exploratory secondary analysis of the APROCCHSS trial of hydrocortisone plus fludrocortisone in septic shock. Adults with septic shock were randomised 1:1 to receive, in a double-blind manner, a 7-day treatment with daily administration of intravenous hydrocortisone 50 mg bolus every 6h and a tablet of 50 μg of fludrocortisone via the nasogastric tube, or their placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included all-cause mortality at intensive care unit (ICU) and hospital discharge, 28-day and 180-day mortality, the number of days alive and free of vasopressors, mechanical ventilation, or organ failure, and ICU and hospital free-days to 90-days. Analysis was done in the intention-to-treat population. The trial was registered at ClinicalTrials.gov (NCT00625209).Findings: Of 1241 patients included in the APROCCHSS trial, CAP could not be ruled in or out in 31 patients, 562 had a diagnosis of CAP (279 in the placebo group and 283 in the corticosteroid group), and 648 patients did not have CAP (329 in the placebo group and 319 in the corticosteroid group). In patients with CAP, there were 109 (39%) deaths of 283 patients at day 90 with hydrocortisone plus fludrocortisone and 143 (51%) of 279 patients receiving placebo (odds ratio [OR] 0·60, 95% CI 0·43-0·83). In patients without CAP, there were 148 (46%) deaths of 319 patients at day 90 in the hydrocortisone and fludrocortisone group and 157 (48%) of 329 patients in the placebo group (OR 0·95, 95% CI 0·70-1·29). There was significant heterogeneity in corticosteroid effects on 90-day mortality across subgroups with CAP and without CAP (p=0·046 for both multiplicative and additive interaction tests; moderate credibility). Of 1241 patients included in the APROCCHSS trial, 648 (52%) had ARDS (328 in the placebo group and 320 in the corticosteroid group). There were 155 (48%) deaths of 320 patients at day 90 in the corticosteroid group and 186 (57%) of 328 patients in the placebo group. The OR for death at day 90 was 0·72 (95% CI 0·53-0·98) in patients with ARDS and 0·85 (0·61-1·20) in patients without ARDS (p=0·45 for multiplicative interaction and p=0·42 for additive interaction). The OR for observing at least one serious adverse event (corticosteroid group vs placebo) within 180 days post randomisation was 0·64 (95% CI 0·46-0·89) in the CAP subgroup and 1·02 (0·75-1·39) in the non-CAP subgroup (p=0·044 for multiplicative interaction and p=0·042 for additive interaction).Interpretation: In a pre-specified subgroup analysis of the APROCCHSS trial of patients with CAP and septic shock, hydrocortisone plus fludrocortisone reduced mortality as compared with placebo. Although a large proportion of patients with CAP also met criteria for ARDS, the subgroup analysis was underpowered to fully discriminate between ARDS and CAP modifying effects on mortality reduction with corticosteroids. There was no evidence of a significant treatment effect of corticosteroids in the non-CAP subgroup.Funding: Programme Hospitalier de Recherche Clinique of the French Ministry of Health, by Programme d'Investissements d'Avenir, France 2030, and IAHU-ANR-0004

Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients

International audienc